Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 20-F, Date: 2018-05-11, XBRL Interactive Financials
Original SEC Filing: Click here
Webplus: SVA/20180511/20-F/1/000.htm SEC Original: tv488620_20f.htm
Webplus: SVA/20180511/20-F/2_EX-4.5/000.htm SEC Original: tv488620_ex4-5.htm
EMPLOYMENT AGREEMENT Agreement” Effective Date Company Executive Group This EMPLOYMENT AGREEMENT (the “ RECITALS A. The Company desires to continue to employ the Executive as its B. The Executive desires to accept such continued employment by the Company as AGREEMENT The parties hereto agree as follows: 1. Position Employment The Executive hereby accepts a position as 2. TERM 3. PROBATION
Webplus: SVA/20180511/20-F/3_EX-8.1/000.htm SEC Original: tv488620_ex8-1.htm
List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Sinovac Biotech Co., Ltd., a PRC company 3. Sinovac Research & Development Co., Ltd., a PRC company 4. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company 5. Sinovac Biomed Co., Ltd., a PRC company
Webplus: SVA/20180511/20-F/4_EX-12.1/000.htm SEC Original: tv488620_ex12-1.htm
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
Webplus: SVA/20180511/20-F/5_EX-12.2/000.htm SEC Original: tv488620_ex12-2.htm
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
Webplus: SVA/20180511/20-F/6_EX-13.1/000.htm SEC Original: tv488620_ex13-1.htm
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weidong Yin Chairman and Chief Executive Officer
Webplus: SVA/20180511/20-F/7_EX-13.2/000.htm SEC Original: tv488620_ex13-2.htm
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Nan Wang Chief Financial Officer
Webplus: SVA/20180511/20-F/8_EX-15.1/000.htm SEC Original: tv488620_ex15-1.htm
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: i) Registration Statement (Form S-8 No. 333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan; and ii) Registration Statement (Form S-8 No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan; of our reports dated May 11, 2018, with
Company Info:
Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 20-F, Date: 2018-05-11, XBRL Interactive FinancialsCIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
NO. 15 ZHI TONG ROAD,, ZHONGGUANCUN TECH PARK, CHANGPING DISTR.
BEIJING 102200
-
- Forum
- Topics
- Last Post
Leave A Comment
You must be logged in to post a comment.